Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Revolution Medicines, Inc. - Common Stock
(NQ:
RVMD
)
101.55
+1.75 (+1.76%)
Streaming Delayed Price
Updated: 12:46 PM EST, Feb 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revolution Medicines, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing
↗
February 18, 2026
a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise...
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
↗
February 17, 2026
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
↗
February 17, 2026
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Via
The Motley Fool
Topics
Regulatory Compliance
Merck In Talks To Acquire Revolution Medicines For About $30B: Report
↗
January 09, 2026
Via
Stocktwits
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report
↗
January 08, 2026
Via
Stocktwits
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake
↗
February 17, 2026
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.
Via
The Motley Fool
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More
↗
February 17, 2026
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.
Via
The Motley Fool
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition
↗
February 17, 2026
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
↗
February 17, 2026
Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge
↗
February 17, 2026
This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.
Via
The Motley Fool
Topics
Regulatory Compliance
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
February 02, 2026
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...
Via
MarketMinute
Topics
ETFs
Government
Initial Public Offering
Why Revolution Medicines Stock Plummeted by Almost 17% Today
↗
January 26, 2026
It doesn't look like the company will end up in the arms of an acquirer soon, after all.
Via
The Motley Fool
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
January 26, 2026
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
January 26, 2026
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...
Via
Finterra
Topics
Economy
Initial Public Offering
Stay updated with the stocks that are on the move in today's pre-market session.
↗
January 26, 2026
Via
Chartmill
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse
↗
January 26, 2026
Merck (NYSE: MRK) reportedly ends discussions to acquire Revolution Medicines (NASDAQ: RVMD) after valuation disagreement.
Via
Benzinga
Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today
↗
January 26, 2026
Via
Stocktwits
Topics
Economy
Stocks
Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity
↗
January 26, 2026
Stifel expects dip-buyers to step in, saying it would be surprised to see RVMD settle meaningfully below $100, calling the failed talks an “M&A clearing event.”
Via
Stocktwits
This Fund Put $3.4 Million Into Navan Despite a 60% Post-IPO Drop
↗
January 24, 2026
Navan delivers AI-powered travel and expense management software for enterprise clients seeking streamlined operations.
Via
The Motley Fool
Topics
Artificial Intelligence
Initial Public Offering
Regulatory Compliance
The Great Mid-Cap Rotation: Fed Rate Cuts Spark a New Bull Run for the 'Forgotten' Middle Market
January 23, 2026
As the Federal Reserve transitions from its long-standing "higher-for-longer" stance to a deliberate cycle of monetary easing, the U.S. equity market is witnessing a profound shift in leadership. For...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Supply Chain
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B
↗
January 12, 2026
When asked about the company’s strategic transactions, CEO Mark Goldsmith said at a conference that the company has a policy of not commenting on rumors or speculation.
Via
Stocktwits
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
January 12, 2026
The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The...
Via
MarketMinute
Topics
Artificial Intelligence
Intellectual Property
Why Revolution Medicines Stock Surged by 11% Today
↗
January 09, 2026
The company might become the latest biotech acquisition story soon.
Via
The Motley Fool
Topics
Intellectual Property
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
↗
January 09, 2026
Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32...
Via
Benzinga
Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
January 08, 2026
In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Get insights into the top gainers and losers of Thursday's after-hours session.
↗
January 08, 2026
Via
Chartmill
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
January 08, 2026
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...
Via
MarketMinute
Topics
Intellectual Property
Stay updated with the stocks that are on the move in today's after-hours session.
↗
January 07, 2026
Via
Chartmill
Revolution Medicines Stock Soars On Report Of AbbVie Takeover
↗
January 07, 2026
The Wall Street Journal reported on Wednesday, citing people familiar with the matter, that AbbVie is in advanced talks to buy Revolution Medicines, while adding it couldn’t learn how much AbbVie is...
Via
Stocktwits
The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens
January 02, 2026
As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
